VTAMA Cream Subgroup Data to Show Atopic Dermatitis
Adults and children with moderate to severe eczema may get a closer look at how this topical treatment performed across patient groups.
Updated on Nov. 5, 2026 in Allergies

Organon presented a pooled post-hoc analysis of Phase 3 data for its VTAMA cream at the 2026 ACAAI Annual Scientific Meeting in Phoenix, Arizona. The analysis looks at how the cream performed across diverse patient subgroups with moderate to severe atopic dermatitis, which is relevant to adults and children ages 2 and older.
Why it matters
For people with moderate to severe atopic dermatitis, the analysis offers a more detailed look at which patient groups responded to the treatment, not just an overall result. Subgroup data help clinicians and patients understand how a topical therapy may perform across different disease severities.
This is a pooled post-hoc analysis of Phase 3 data from the ADORING program, which included two 8-week pivotal trials and a 48-week open-label extension in patients with moderate to severe atopic dermatitis. Specific efficacy figures and subgroup results were not included in the available information, and post-hoc analyses are generally considered hypothesis-generating rather than confirmatory.
The players
Organon
A global healthcare company headquartered in Jersey City, New Jersey, with a portfolio of over 70 products in Women's Health and General Medicines, sold in more than 140 markets.
American College of Allergy, Asthma and Immunology (ACAAI)
A professional medical society that hosts an annual scientific meeting for allergists, immunologists, and related specialists to share clinical research.
The details
The analysis groups patients by baseline characteristics, including the percentage of body surface area affected, to see whether VTAMA cream's effect varies across subgroups. VTAMA is an aryl hydrocarbon receptor agonist, a class of drug that works by activating a receptor involved in regulating skin inflammation and barrier function. It is already approved for plaque psoriasis in adults and for atopic dermatitis in adults and children ages 2 and older, making it the only drug of its class with both indications.
Timeline
2026: Organon presents the analysis at the ACAAI Annual Scientific Meeting in Phoenix, Arizona (specific date not given).
Health Landscape
Topical non-steroidal options for atopic dermatitis have expanded beyond traditional corticosteroids, and VTAMA's approval for both psoriasis and atopic dermatitis places it in a small group of therapies with dual indications. Subgroup analyses like this one help show how newer topical treatments may fit across the range of disease severity seen in clinical practice.
If you or a family member has moderate to severe atopic dermatitis, this analysis may be worth raising with a dermatologist or allergist when discussing treatment options. Anyone considering a topical therapy should ask about how the medication has performed in patients with similar disease severity and body surface area involvement.
The takeaway
Subgroup data can clarify how a treatment may perform across different patients, so it is worth asking your dermatologist or allergist how their findings apply to your situation. Keep an eye out for the full published results of this analysis to see the specific efficacy and safety data.
Further reading
For more background on how these conditions are managed, explore our Allergies coverage.
Source note: This article includes information reported by Firstwordpharma.





